# BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

> **NCT02871635** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 147 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** BI 695501
- **DRUG:** HUMIRA

## Key facts

- **NCT ID:** NCT02871635
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-28
- **Primary completion:** 2019-04-30
- **Final completion:** 2019-05-13
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2020-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02871635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02871635, "BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02871635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*